Welcome to our dedicated page for Nexalin Tech news (Ticker: NXLIW), a resource for investors and traders seeking the latest updates and insights on Nexalin Tech stock.
Nexalin Technology Inc. (NXLIW) pioneers non-invasive neurostimulation therapies for mental health conditions, offering drug-free alternatives through its transcranial electrical stimulation (TES) and deep intracranial frequency stimulation (DIFS) technologies. This page provides investors, researchers, and healthcare professionals with essential updates on clinical advancements, regulatory milestones, and strategic initiatives shaping the future of neurohealth innovation.
Access real-time announcements covering FDA clearances, partnership agreements, clinical trial outcomes, and product development progress. Our curated repository ensures you stay informed about Nexalin’s contributions to treating anxiety, depression, insomnia, and related neurological disorders through bioelectronic medical solutions.
Discover updates categorized for clarity: earnings reports detailing financial health, peer-reviewed study publications validating therapeutic efficacy, and collaborations advancing digital health integration. Each release is vetted for relevance to investor decision-making and industry trends in neurostimulation.
Bookmark this page for streamlined access to authoritative NXLIW news. Regularly updated content supports informed analysis of the company’s role in transforming mental health treatment paradigms through safe, clinically validated technologies.
Nexalin Technology announced that the FDA has provided feedback and reached consensus on the design for clinical studies of its Gen-3 HALO Clarity™ headset. These studies, focusing on anxiety and insomnia, are set to commence in Q3 2024. Each study will involve 75 patients receiving active treatment and 75 receiving sham treatment. The HALO device uses Deep Intracranial Frequency Stimulation (DIFS™) to potentially offer an effective alternative to pharmacological treatments. Following the studies, Nexalin plans to submit a De Novo request to the FDA, seeking a new marketing pathway for the device.
The production of over 500 units of the HALO headset has started to support these studies. Nexalin aims to manage the patient-physician relationship through a virtual clinic model, allowing at-home use with remote monitoring by a physician. CEO Mark White sees this as a significant step towards revolutionizing mental health treatment standards.
Nexalin Technology announced that its new division, Nexalin America, has joined the National Traumatic Brain Injury (TBI) Registry Coalition. This Coalition comprises private sector and non-profit organizations dedicated to advancing research, raising awareness, and supporting clinical trials for TBI, affecting millions annually. Members include the NFL Players Association, Spaulding Rehabilitation at Mass General, United States Brain Injury Alliance, Abbott, and American Academy of Neurology. Nexalin America will leverage its neurostimulation technology expertise to contribute to developing a national TBI registry. CEO Mark White highlighted this partnership as a significant step towards combating brain injuries through advanced technology and collaborative research.
Nexalin Technology, Inc. is hosting an exclusive live investor webinar on May 23, 2024, featuring CEO Mark White discussing the company's clinical data on its deep brain stimulation device and new clinic model. Investors can register for the event and submit questions online.
FAQ
What is the current stock price of Nexalin Tech (NXLIW)?
